Related Experiment Video
Updated: Jun 17, 2026
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
Asymmetric dimethylarginine (ADMA) as a possible risk marker for ischemic stroke
Yasuhiro Nishiyama1, Masayuki Ueda, Ken-Ichiro Katsura
1Department of Internal Medicine, Nippon Medical School, Tokyo, Japan. nomo16@nms.ac.jp
Insights
Asymmetric dimethylarginine (ADMA) levels are linked to vascular risk factors like hypertension and dyslipidemia. Higher ADMA concentrations were observed in stroke patients, suggesting its potential as a marker for ischemic stroke risk.
Area of Science:
- Cardiovascular Research
- Biomarker Discovery
- Vascular Biology
Background:
- Asymmetric dimethylarginine (ADMA) impairs vascular function by inhibiting nitric oxide synthesis.
- Understanding ADMA's role in vascular health is crucial for identifying cardiovascular disease risks.
Purpose of the Study:
- To investigate the relationship between ADMA concentration and vascular risk factors in individuals undergoing routine medical check-ups.
- To compare ADMA levels in subjects with and without a history of ischemic stroke.
Main Methods:
- Assessed ADMA concentration, lipid profiles, and vascular risk factors in 116 individuals during annual medical examinations.
- Employed univariate and multivariate analyses to identify factors associated with ADMA levels.
- Measured ADMA concentration in 50 age-matched patients with ischemic stroke.
Main Results:
- Mean serum ADMA concentration was significantly higher in ischemic stroke patients compared to the general check-up group.
- ADMA levels in the check-up group correlated with age, hypertension, dyslipidemia, fasting blood glucose, and cholesterol.
- Hypertension and dyslipidemia were identified as independent determinants of ADMA concentration.
Conclusions:
- Serum ADMA concentration is significantly associated with common vascular risk factors in individuals receiving routine medical evaluations.
- ADMA may serve as a valuable predictive biomarker for the future development of ischemic stroke.
Background:
Asymmetric dimethylarginine (ADMA) affects vascular function by blocking nitric oxide synthesis. We examined the relationship of ADMA concentration to vascular risk factors in subjects who have undergone annual medical check-up.
Methods:
ADMA concentration, lipid profile and vascular risk factors were assessed during an annual medical examination in 116 subjects (mean age 58.7years). Univariate and multivariate analyses were carried out to assess factors associated with ADMA concentration. ADMA concentration was also assessed in 50 age-matched patients with ischemic stroke.
Results:
Mean serum ADMA concentration was significantly higher in the ischemic stroke patients than the medical check-up subjects (0.461+/-0.076 versus 0.433+/-0.056mumol/l; P=0.022). Univariate analysis showed that ADMA concentration in the medical check-up subjects was significantly associated with age, hypertension, dyslipidemia, fasting blood glucose, total and LDL cholesterol concentrations. Multiple stepwise linear regression analysis showed that hypertension (beta=0.25, P=0.008) and dyslipidemia (beta=0.19, P =0.048) were significant independent determinants of ADMA concentration. ADMA concentration increased progressively with number of vascular risk factors, with a significant (P=0.001) difference between subjects with no risk factors and subjects with > or =2 risk factors.
Conclusions:
Serum ADMA concentration was significantly associated with vascular risk factors in subjects undergoing routine medical check-up. ADMA concentration warrants further examination as a possible marker of future development of ischemic stroke.
Related Concept Videos
01:26Atherosclerosis III: Management
01:30Coronary Artery Disease I: Introduction